Probiotics for prevention of Clostridium difficile infection

Current Opinion in Gastroenterology

Volumn 34, Issue 1, 2018, Pages 3-10

  Mills, John P ^a   Rao, Krishna ^a   Young, Vincent B ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

bacteriophage therapy; Clostridium difficile infection; fecal microbiota transplantation; prebiotics; probiotics

Indexed keywords

BILE ACID; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT;

BACILLUS THURINGIENSIS; BACTERIAL COLONIZATION; BACTERIAL SECRETION SYSTEM; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BILE ACID METABOLISM; CLOSTRIDIUM; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM SCINDENS; DRUG EFFICACY; DRUG SAFETY; ENTEROCOCCUS; FECAL MICROBIOTA TRANSPLANTATION; HIGH RISK POPULATION; HOMEOSTASIS; HUMAN; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; MICROFLORA; NONHUMAN; PHAGE THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; REVIEW; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM INFECTION; DIET THERAPY; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PHYSIOLOGY; PROCEDURES; PSEUDOMEMBRANOUS COLITIS;

CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; HUMANS; MICROBIOTA; PRIMARY PREVENTION; PROBIOTICS;

EID: 85036645553     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000410     Document Type: Review

References (51)

1. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825-834.
2. Zimlichman E, Henderson D, Tamir O, et al. Healthcare-associated infections: a meta-analysis of costs and financial impact on the US healthcare system. JAMA Intern Med 2013; 173:2039-2046.
3. Biggest Threats j Antibiotic/Antimicrobial Resistancej CDC. 2017. https://www.cdc.gov/drugresistance/biggest-threats.html. Accessed 10 September 2017.
4. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365:1693-1703.
5. Alasmari F, Seiler SM, Hink T, et al. Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin Infect Dis 2014; 59: 216-222.
6. Vonberg RP, Kuijper EJ, Wilcox MH, et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008; 14(Suppl 5): 2-20.
7. Theriot CM, Young VB. Interactions between the gastrointestinal microbiome and Clostridium difficile. Annu Rev Microbiol 2015; 69:445-461.
8. Abt MC, McKenney PT, Pamer EG. Clostridium difficile colitis: pathogenesis and host defence. Nat Rev Microbiol 2016; 14:609-620.
9. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 2015; 313:398-408.
10. Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One 2014; 9:e98400.
11. McFarland LV. From yaks to yogurt: the history, development, and current use of probiotics. Clin Infect Dis 2015; 60(Suppl 2):S85-S90.
12. Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11:506-514.
13. Carasi P, Trejo FM, Pé rez PF, et al. Surface proteins from Lactobacillus kefir antagonize in vitro cytotoxic effect of Clostridium difficile toxins. Anaerobe 2012; 18:135-142.
14. Castagliuolo I, Riegler MF, Valenick L, et al. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67:302-307.
15. Solomon K. The host immune response to Clostridium difficile infection. Ther Adv Infect Dis 2013; 1:19-35.
16. Hudson LE, Anderson SE, Corbett AH, Lamb TJ. Gleaning insights from fecal microbiota transplantation and probiotic studies for the rational design of combination microbial therapies. Clin Microbiol Rev 2017; 30:191-231.
17. Shen NT, Maw A, Tmanova LL, et al. Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology 2017; 152: 1889-1900; e9.
18. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-455.
19. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108:478-498; quiz 499.
20. Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013; (5):Cd006095.
21. Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA 2015; 313:1719-1727.
22. Orenstein R, Dubberke E, Hardi R, et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study. Clin Infect Dis 2016; 62:596-602.
23. Dubberke ER, Mullane KM, Gerding DN, et al. Clearance of vancomycinresistant Enterococcus concomitant with administration of a microbiotabased drug targeted at recurrent Clostridium difficile infection. Open Forum Infect Dis 2016; 3:ofw133.
24. Khanna S, Pardi DS, Kelly CR, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis 2016; 214:173-181.
25. Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. Gastroenterology 2017; 152:799-811; e7.
26. Nale JY, Spencer J, Hargreaves KR, et al. Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob Agents Chemother 2016; 60:968-981.
27. Rao K, Safdar N. Fecal microbiota transplantation for the treatment of Clostridium difficile infection. J Hosp Med 2016; 11:56-61.
28. Rao K, Young VB. Fecal microbiota transplantation for the management of Clostridium difficile infection. Infect Dis Clin North Am 2015; 29:109-122.
29. Ehrhardt S, Guo N, Hinz R, et al. Saccharomyces boulardii to prevent antibiotic-associated diarrhea: a randomized, double-masked, placebo-controlled trial. Open Forum Infect Dis 2016; 3:ofw011.
30. Barker AK, Duster M, Valentine S, et al. A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO). J Antimicrob Chemother 2017; 72:3177-3180.
31. Gibson GR, Probert HM, Loo JV, et al. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics.NutrResRev2004; 17:259-275.
32. Slavin J. Fiber and prebiotics: mechanisms and health benefits. Nutrients 2013; 5:1417-1435.
33. Ratsep M, Koljalg S, Sepp E, et al. A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection. Anaerobe 2017; 47:94-103.
34. Valdes-Varela L, Hernández-Barranco AM, Ruas-Madiedo P, et al. Effect of Bifidobacterium upon Clostridium difficile growth and toxicity when cocultured in different prebiotic substrates. Front Microbiol 2016; 7:738.
35. Ripert G, Racedo SM, Elie AM, et al. Secreted compounds of the probiotic Bacillus clausii Strain O/C inhibit the cytotoxic effects induced by Clostridium difficile and Bacillus cereus toxins. Antimicrob Agents Chemother 2016; 60:3445-3454.
36. Aktories K, Schwan C, Jank T. Clostridium difficile toxin biology. Annu Rev Microbiol 2017; 71:281-307.
37. Spinler JK, Auchtung J, Brown A, et al. Next-generation probiotics targeting Clostridium difficile through precursor-directed antimicrobial biosynthesis. Infect Immun 2017; 85: e00303-17. https://doi.org/10.1128/IAI.00303-17.
38. Hanchi H, Hammami R, Gingras H, et al. Inhibition of MRSA and of Clostridium difficile by durancin 61A: synergy with bacteriocins and antibiotics. Future Microbiol 2017; 12:205-212.
39. Winston JA, Theriot CM. Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract. Anaerobe 2016; 41:44-50.
40. Buffie CG, Bucci V, Stein RR, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2015; 517:205-208.
41. Weingarden AR, Chen C, Zhang N, et al. Ursodeoxycholic acid inhibits clostridium difficile spore germination and vegetative growth, and prevents the recurrence of ileal pouchitis associated with the infection. J Clin Gastroenterol 2016; 50:624-630.
42. Brouwer MS, Roberts AP, Hussain H, et al. Horizontal gene transfer converts nontoxigenic Clostridium difficile strains into toxin producers. Nat Commun 2013; 4:2601.
43. Dubberke Er, L.C.O.R.K.S.H.G.F.J. Efficacy and safety of RBX2660 for the prevention of recurrent. In IDWeek 2016. 2016. Idsa.
44. Press Releases j Investor & Media j Seres Therapeutics. 2017. Available from: http://ir.serestherapeutics.com/phoenix.zhtmlc=254006&p=irol-newsArticle&ID=2240833. Accessed 10 September 2017.
45. SER-262 versus placebo in adults with primary Clostridium difficile infection to prevent recurrence-full text view-ClinicalTrials.gov. 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT02830542. Accessed 10 September 2017.
46. ECOSPOR III-SER-109 versus placebo in the treatment of adults with recurrent Clostridium difficile infection-https://clinicaltrials.gov/ct2/show/NCT03183128. full text view-ClinicalTrials.gov. 2017. Accessed 13 October 2017.
47. Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med 2016; 165:609-616.
48. Hota SS, Sales V, Tomlinson G, et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: an open-label, randomized controlled trial. Clin Infect Dis 2017; 64:265-271.
49. Maziade PJ, Pereira P, Goldstein EJ. A decade of experience in primary prevention of Clostridium difficile infection at a community hospital using the probiotic combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K). Clin Infect Dis 2015; 60(Suppl 2):S144-S147.
50. Jenior ML, Leslie JL, Young VB, Schloss PD. Clostridium difficile colonizes alternative nutrient niches during infection across distinct murine gut microbiomes. mSystems 2017; 2: e00063-17. https://doi.org/10.1128/mSystems.00063-17.
51. Bucci V, Tzen B, Li N, et al. MDSINE: Microbial Dynamical Systems INference Engine for microbiome time-series analyses. Genome Biol 2016; 17:121.